Browsing Tag
specialty pharma
2 posts
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Evoke Pharma stock surges 130% as QOL Medical signs definitive $11-per-share acquisition agreement
Find out how Evoke Pharma’s $11-per-share acquisition by QOL Medical is reshaping specialty pharma and why investors are applauding this record premium.